XCath Successfully Performs World’s First Public Telerobotic Mechanical Thrombectomy Demo at Abu Dhabi Global Healthcare Week
May 16 2024 - 10:05AM
Business Wire
Model trial reveals opportunities and
advancements in critical interventional procedures
XCath, an early-stage medical device company dedicated to
expanding endovascular treatment modalities through its smart
steerable guidewires and robotic systems, successfully completed a
first-of-its-kind live telerobotic trial for stroke treatment
between Abu Dhabi and South Korea at Abu Dhabi Global Healthcare
Week (ADGHW).
In the live demonstration, Vitor Mendes Pereira, M.D., performed
a mechanical thrombectomy procedure from Abu Dhabi on a simulated
patient in South Korea. Dr. Pereira completed the procedure to
remove a blood clot in the brain in a matter of minutes, reporting
low latency and a reliable connection to the robotic device in
South Korea.
“This successful telerobotic demonstration marks a key
validation of our platform’s potential to improve treatment of
emergent conditions like stroke,” said Eduardo Fonseca, CEO of
XCath. “As one of the leading advocates for telerobotic technology,
Dr. Pereira was able to demonstrate how our technology could be
used to transform patients’ lives across the globe.”
Time to treatment is a critical determinant in stroke outcomes,
as patients risk losing more than 2 million brain cells per minute
until treatment is administered. By creating remote treatment
options that connect patients to stroke specialists, regardless of
geographic location, telerobotic interventions can save precious
time and limit mortality and morbidity rates. The XCath platform
can also expand treatment options and improve patient outcomes for
a range of acute neurovascular conditions.
“Today, we witnessed a groundbreaking moment with the world’s
first telerobotic manual thrombectomy on a model, from Abu Dhabi to
Seoul,” said Fred Moll, M.D., a surgical robotics pioneer and
founder of Intuitive Surgical. “This pioneering achievement is not
just a first, but a crucial stepping stone towards regulatory and
industry support, ultimately leading to widespread acceptance and
adoption. In the field of endovascular care, particularly in stroke
treatment where every minute counts, this technology holds
transformative potential.”
The live simulated thrombectomy case aimed to demonstrate that
XCath’s remote setup could overcome latency and overall performance
questions associated with remote procedures. Dr. Pereira, a
neurosurgery pioneer and Director of Endovascular Research and
Innovation at St. Michael’s Hospital, University of Toronto,
Canada, performed the robotic procedure using a robotic controller
located in Abu Dhabi, while the silicone model and the bedside unit
were situated in South Korea, 4,318 miles away. The procedure
utilized neurovascular devices from Stryker, including the AXS
Infinity LS, Trevo Trakb21 and Trevo NXT.
For more information about ADGHW, visit https://www.adghw.com/.
To learn more about XCath, visit https://www.xcath.com/.
About XCath
Founded in 2017, XCath is a dynamic startup at the cutting edge
of revolutionary medical robotics, nanorobotics and materials
science. XCath develops next-generation endovascular robotic
systems and steerable guidewires to treat life-threatening
conditions like cerebrovascular disorders. With strategically
located campuses in Houston, Texas – home to the world's largest
medical center – and Pangyo, South Korea, often referred to as the
Silicon Valley of Korea, XCath is committed to bringing its
innovative solutions to patients around the world.
The XCath steerable guidewires and endovascular robotic systems
are currently under development. They are not yet cleared for
commercial distribution in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240516144756/en/
Dan Ventresca Matter Health for XCath XCath@matternow.com